# P3 Health Partners Inc. (PIII) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare. Price $9.35, market value $1.9 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). P3 Health Partners Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 1.2×**. Each dollar of revenue is priced at 1.2×.

## Profitability
- **Operating margin: -9.9%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -10.1%**. The company reported a net loss over the last twelve months.
- **Return on equity: 95.3%**. A 95.3% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: -126.0%**. Return on all capital, debt included, is -126.0%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -15.0%**. Each dollar of assets produces -15.0% of profit.

## Growth
- **Revenue growth (1 yr): -2.8%** (3-yr 11.6%/yr, 5-yr 58.6%/yr). Revenue fell 2.8% over the last year, against 58.6% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 16.3%**. Earnings per share rose 16.3%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Net debt / EBITDA: net cash**. P3 Health Partners Inc. holds more cash than debt.
- **Altman Z-score: 1.94**. A Z-score of 1.94 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. P3 Health Partners Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (2 analysts). 2 analysts cover P3 Health Partners Inc.; the consensus is buy, with an average price target of $18.00 (+93% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 6.7%** (YTD 167.9%, 3-mo -19.3%). The shares are up 6.7% over twelve months including dividends.
- **From 52-week high: -44.6%** (515.1% above the low). Trading 45% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 43**. An RSI of 43 is neutral.
- **Beta (1 yr): -1.55** (volatility 218%). Beta of -1.55 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PIII · Page: https://foliofundamentals.com/stocks/piii

Not investment advice.